Document:

Ex. 10.208 FarhatEmploymentAgreement

Exhibit 10.208

EXECUTION COPY

EXECUTIVE EMPLOYMENT AGREEMENT

THIS AGREEMENT (the “Agreement”) is hereby entered into as of July 17, 2012, by and between American Medical Systems, Inc.  (the “Company”) and Camille Farhat (“Executive”) (hereinafter collectively referred to as “the parties”). 
In consideration of the respective agreements of the parties contained herein, it is agreed as follows:

		
	1.
	Term.   The initial term of Executive’s employment under this Agreement shall be for the period commencing on September 4, 2012 (The “Employment Commencement Date”) and ending, subject to earlier termination  as set forth in Section 5, on the third anniversary of the Employment Commencement Date (the “Employment Term”).   The Employment Term shall automatically renew for one additional one (1) year period unless a notice of non-renewal is delivered by either party no later than 120 days prior to the expiration of the initial Employment Term. 

		
	2.
	Employment.  During the Employment Term: 

		
	a.
	Executive shall be assigned with the duties and responsibilities of President of the Company, as may be reasonably be assigned to Executive from time to time by the Chief Executive Officer of Endo Health Solutions, Inc. (“Endo”).  Executive shall perform such duties, undertake the responsibilities, and exercise the authorities customarily performed, undertaken and exercised by persons situated in a similar executive capacity at a similar company. 

		
	b.
	Executive shall devote Executive’s full-time business attention to the business and affairs of the Company. Notwithstanding the foregoing, Executive may, subject to the approval of the Company, (i) serve on civil, charitable or non-profit boards or committees, (ii) serve on one public company board of directors and (iii) manage personal and family investments and affairs, participate in industry organizations and deliver lectures at educational institutions, so long as such service and activity, does not interfere, individually or in the aggregate, with the performance of his responsibilities hereunder and subject to the Company's code of conduct and other applicable policies as in effect from time to time. 

		
	c.
	Executive shall be subject to and shall abide by each of the Company and Endo’s personnel and compliance policies applicable and communicated in writing to senior executives.

Exhibit 10.208

		
	3.
	Annual Compensation and Equity Grants.

  
		
	a.
	Base Salary.  The Company agrees to pay or cause to be paid to Executive during the Employment Term a base salary at the rate of $550,000 per annum or such increased amount as the Chief Executive Officer of Endo or the Compensation Committee of Endo may from time to time determine, and which shall be reviewed for such increase annually, with the first such review to occur in March 2013 (hereinafter referred to as the “Base Salary”).  Such Base Salary shall be payable in accordance with the Company’s customary practices applicable to its executives, but no less frequently than monthly. 

		
	b.
	Incentive Compensation.  For each fiscal year of the Company ending during the Employment Term, beginning with the 2012 fiscal year, Executive shall be eligible to participate in the Company’s annual incentive plan.  Executive shall be eligible to receive a target annual cash bonus of 60% of Base Salary (such target bonus, as may hereafter be modified, the “Target Bonus”), with the opportunity to receive a maximum annual cash bonus in accordance with the terms of the applicable Company annual cash bonus plan as in effect immediately prior to the Employment Commencement Date.  Any bonus payment shall be subject to the achievement of performance targets as set by the Compensation Committee of the Board of Directors of Endo (the “Committee”).   Such annual cash bonus shall be paid in no event later than March 15th of the taxable year following the end of the taxable year to which the performance targets relate, provided that Executive is employed by the Company through December 31, 2012.  Notwithstanding the foregoing, for 2012, Executive’s Target Bonus shall be pro-rated to reflect the time period between the Employment Commencement Date and the last day of the applicable performance year and Executive’s actual bonus shall be no less than $110,000, provided that the Company’s minimum net operating income targets established by the Committee for the 2012 bonus program are achieved and Executive is employed by the Company through December 31, 2012.  

		
	c.
	Sign-On Bonus. On the first regular payroll period payment date following the Employment Commencement Date, the Company shall pay Executive a sign-on cash bonus of $200,000. The Company is required to withhold tax at the time of payment of this bonus. If Executive’s employment with the Company is terminated by the Company for Cause (as described in Section 5(c)), or by Executive without Good Reason (as described in Section 5(f)), within 18 months of the Effective Date, Executive must repay to the Company the full amount of the sign-on cash bonus.  Any such repayment must be made within 90 days of such termination.

Exhibit 10.208

		
	d.
	Equity Compensation.  

		
	i.
	General.  For each fiscal year or part thereof during the Employment Term, Executive shall be eligible to receive equity-based compensation with a targeted grant date fair market value equal to 250% of Executive’s Base Salary for such fiscal year; provided, however, that the equity-based compensation for fiscal year 2012 shall be prorated to reflect the time period between the Employment Commencement Date and the end of fiscal year 2012.  All such equity-based awards shall be subject to the terms and conditions set forth in the applicable plan and agreements, and in all cases shall be as determined by the Committee; provided, however, that such equity-based compensation shall be on terms and conditions substantially similar to those applicable to similarly situated senior executives of Endo.   

		
	ii.
	Initial Stock Option Grant.  On the first trading day following the Employment Commencement Date, Endo shall grant Executive stock options under Endo’s equity incentive plans (the “Initial Stock Options”) with a grant date fair market value equal to 125% of Base Salary (using a Black-Scholes valuation based on the closing price of Endo’s common stock on the grant date with methodology determined by the Committee in its sole discretion). Such initial grant of stock options shall vest ratably over a four-year period, 25% on each anniversary of the grant date, provided Executive is employed on such dates by the Company.  All such stock options shall be subject to the terms and conditions set forth in the applicable plan and applicable award agreement attached hereto as Exhibit A. 

		
	iii.
	Initial Restricted Stock Unit Grant.  On the first trading day following the Employment Commencement Date, Endo shall grant Executive restricted stock units under Endo’s equity incentive plans (the “Initial RSUs”).  The number of Initial RSUs shall have a value equal to 125% of Base Salary, divided by the Fair Market Value (as defined in the applicable equity incentive plan) of a share of Endo’s common stock as of the grant date (rounded down to the nearest whole share).  Such initial grant of restricted stock units shall vest ratably over a four-year period, 25% on each anniversary of the grant date, provided Executive is employed on such dates by the Company.  All such restricted stock units shall be subject to the terms and conditions of the applicable plan and applicable award 

Exhibit 10.208

agreement attached hereto as Exhibit B. 

		
	4.
	Other Benefits. 

		
	a.
	Employee Benefits.  Except as set forth below, during the Employment Term, Executive shall be entitled to participate in all employee benefit plans, practices and programs maintained by Endo and made available to employees Endo generally, including, without limitation, all pension, retirement, profit sharing, savings, medical, hospitalization, disability, dental, life or travel accident insurance benefit plans, to the extent Executive is eligible under the terms of such plans.  Executive’s participation in such plans, practices and programs shall be on the same basis and terms as are applicable to employees of the Company generally.     

		
	b.
	Executive Benefits.  During the Employment Term, Executive shall be entitled to participate in all executive benefit or incentive compensation plans now maintained or hereafter established by Endo for the purpose of providing compensation and/or benefits to comparable executive employees of Endo including, but not limited to, Endo’s deferred compensation plans and any supplemental retirement, deferred compensation, supplemental medical or life insurance or other bonus or incentive compensation plans. Unless otherwise provided herein, Executive’s participation in such plans shall be on the same basis and terms, as other senior executives of Endo. No additional compensation provided under any of such plans shall be deemed to modify or otherwise affect the terms of this Agreement or any of Executive’s entitlements hereunder.  The Executive is responsible for any taxes that may be due based upon the value of the benefits provided.  

		
	c.
	Business Expenses. Upon submission of proper invoices in accordance with the Company’s normal procedures, Executive shall be entitled to receive prompt reimbursement of all reasonable out-of-pocket business, entertainment and travel expenses incurred by Executive in connection with the performance of Executive’s duties hereunder and otherwise incurred in accordance with the Company’s travel and entertainment policy in effect from time to time.  Such reimbursement shall be made as soon as practicable and in no event later than the end of the calendar year following the calendar year in which the expenses were incurred. 

		
	d.
	Office and Facilities.  During the Employment Term, Executive shall be provided with an appropriate office, with such secretarial and other support facilities as are commensurate with Executive’s status with the Company, which facilities shall be adequate for the performance of Executive’s duties hereunder.  
 

Exhibit 10.208

		
	e.
	Vacation and Sick Leave.  Executive shall be entitled, without loss of pay, to absent himself voluntarily from the performance of Executive’s employment under this Agreement, pursuant to the following:

		
	i.
	Executive shall be entitled to annual vacation in accordance with the vacation policies of the Company as in effect from time to time, which shall in no event be less than four weeks per year; vacation must be taken at such time or times as approved by the CEO; and

		
	ii.
	Executive shall be entitled to sick leave (without loss of pay) in accordance with the Company’s policies as in effect from time to time. 

		
	5.
	Termination.  The Employment Term and Executive's employment hereunder may be terminated under the circumstances set forth below; provided, however, that notwithstanding anything contained herein to the contrary, Executive shall not have any duties or responsibilities to the Company after Executive's termination of employment that would preclude Executive from having a “separation from service” from the Company within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), upon such termination of employment.

		
	a.
	Disability. The Company may terminate Executive’s employment, on written notice to Executive after having reasonably established Executive’s Disability.  For purposes of this Agreement, Executive will be deemed to have a “Disability” if, as a result of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months, Executive is unable to perform the core functions of Executive’s position (with or without reasonable accommodation) or is receiving income replacement benefits for a period of three months or more under an accident and health plan covering employees of the Company.  Executive shall be entitled to the compensation and benefits provided for under this Agreement for any period prior to Executive’s termination by reason of Disability during which Executive is unable to work due to a physical or mental infirmity in accordance with the Company’s policies for similarly-situated executives.   

		
	b.
	Death.  Executive’s employment shall be terminated as of the date of Executive’s death. 

		
	c.
	Cause.  The Company may terminate Executive’s employment for “Cause” by providing a Notice of Termination (as defined in Section 6 below) that notifies Executive of his termination for Cause, effective as of the date of such notice. “Cause” shall mean, for 

Exhibit 10.208

purposes of this Agreement: (a) the continued failure by Executive to use good faith efforts in the performance of Executive’s duties under this Agreement (other than any such failure resulting from Disability or other allowable leave of absence); (b) the criminal felony indictment of Executive by a court of competent jurisdiction; (c) the engagement by Executive in misconduct that has caused, or is reasonably likely to cause, material harm (financial or otherwise) to the Company or its affiliates; such harm may be caused by, without limitation, (i) the unauthorized disclosure of material secret or Confidential Information (as defined in Section 9(d)) of the Company or any of its affiliates, (ii) the debarment of the Company or any of its affiliates by the U.S. Food and Drug Administration or any successor agency (the “FDA”), or (iii) the registration of the Company or any of its affiliates with the U.S. Drug Enforcement Administration of any successor agency (the “DEA”) to be revoked; (d) the debarment of Executive by the FDA, (e) the continued material breach by Executive of this Agreement, or (f) Executive makes, or is found to have made, a certification relating to the Company’s financial statements and public filings that is known to the Executive to be false. Notwithstanding the foregoing, prior to having “Cause” for Executive’s termination (other than as described in clauses (b) and (d) thereof), the Company or Endo must deliver a written demand to Executive which specifically identifies the conduct that may provide grounds for Cause, and the Executive must have failed to cure such conduct (if curable) within fifteen (15) days after such demand. References to the Company in subsections (a) through (f) of this paragraph shall also include affiliates of the Company. 

		
	d.
	Without Cause.  The Company may terminate Executive’s employment other than for Cause, Disability or death.  The Company shall deliver to Executive a Notice of Termination (as defined in Section 6 below) not less than thirty (30) days prior to the termination of Executive’s employment other than for Cause, Disability or death, and the Company shall have the option of terminating Executive’s duties and responsibilities prior to the expiration of such thirty-day notice period.  

		
	e.
	Termination by Executive Without Good Reason.  Executive may voluntarily terminate Executive’s employment without Good Reason by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive’s employment, and the Company shall have the option of terminating Executive’s duties and responsibilities prior to the expiration of such thirty-day notice period. 

		
	f.
	Termination by Executive for Good Reason.  Executive may terminate employment with the Company for Good Reason (as 

Exhibit 10.208

defined below) by delivering to the Company a Notice of Termination (as defined in Section 6 below) not less than thirty (30) days prior to the termination of Executive’s employment for Good Reason. The Company shall have the option of terminating Executive’s duties and responsibilities prior to the expiration of such thirty-day notice period. For purposes of this Agreement, “Good Reason” means any of the following: (a) a material diminution in Executive’s salary or benefits; (b) a material diminution, without Executive’s written consent, of his position, responsibilities, duties or authorities from those in effect as of the Employment Commencement Date; (c) any change in reporting structure such that Executive is required to report to someone other than the Chief Executive Officer of Endo or the Board of Directors of Endo; (d) the Company changing its headquarters to a location that is more than fifty (50) miles from the Company’s current headquarters (except for any such change in location that is not materially adverse to Executive); or (e) any material breach by the Company of its obligations under this Agreement. Executive shall provide notice of the existence of the Good Reason condition within ninety (90) days of the date Executive learns of the condition, and the Company shall have a period of thirty (30) days during which it may remedy the condition, and in case of full remedy such condition shall not be deemed to constitute Good Reason hereunder. 

		
	6.
	Notice of Termination.  Any purported termination by the Company or by Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice that indicates a termination date, the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive’s employment under the provision so indicated. For purposes of this Agreement, no such purported termination of Executive’s employment hereunder shall be effective without such Notice of Termination (unless waived by the party entitled to receive such notice, in the manner described in Section 15(d)).  

		
	7.
	Compensation Upon Termination.

		
	a.
	Termination by the Company for Cause or by Executive Other Than for Good Reason During the Employment Term. If Executive’s employment is terminated (A) by the Company for Cause or (B) by Executive for any reason, other than for Good Reason, in either case during the Employment Term, the Company shall provide Executive with the following payments and benefits:

		
	i.
	any accrued and unpaid Base Salary; 

Exhibit 10.208

		
	ii.
	any annual bonus earned but unpaid in respect of any completed fiscal year preceding the termination date; 

		
	iii.
	reimbursement for any and all monies advanced or expenses incurred in connection with Executive’s employment for reasonable and necessary expenses incurred by Executive on behalf of the Company for the period ending on the termination date; 

		
	iv.
	any accrued and unpaid vacation pay; 

		
	v.
	any previous compensation that Executive has previously deferred (including any interest earned or credited thereon), in accordance with the terms and conditions of the applicable deferred compensation plans or arrangements then in effect, to the extent vested as of Executive’s termination date; and

		
	vi.
	any amount or benefit as provided under any plan, program, agreement or corporate governance document of the Company or its affiliates that are then-applicable (the “Company Arrangements”), in accordance with the terms thereof. 

(the foregoing items in Sections 7(a)(i) through 7(a)(vi) being collectively referred to as the “Accrued Compensation”). 

		
	b.
	Termination by the Company for Disability. If Executive’s employment is terminated by the Company for Disability, the Company shall pay or provide to Executive:

		
	iii.
	the Accrued Compensation; 

		
	iv.
	an amount equal to the Incentive Compensation that Executive would have been entitled to receive in respect of the fiscal year in which Executive’s termination date occurs, had Executive continued in employment until the end of such fiscal year, which amount, determined based on the Company’s actual performance for such year relative to the performance goals applicable to Executive, shall be multiplied by a fraction (A) the numerator of which is the number of days in such fiscal year through termination date and (B) the denominator of which is 365 (the “Pro-Rata Bonus”) and shall be payable in a lump sum payment at the time such bonus or incentive awards are payable to other participants;

Exhibit 10.208

		
	v.
	accelerated vesting, non forfeitability and exercisability, as of the termination date, of the Initial Stock Options and the Initial RSUs as provided for in the equity incentive plan or plans pursuant to which the Initial Stock Options and Initial RSUs were granted; and

		
	vi.
	continued coverage for Executive and Executive’s dependents under any health, medical, dental, vision or life insurance program or policy in which Executive was eligible to participate as of the time of Executive’s employment termination, for two (2) years following such termination on terms no less favorable to Executive and Executive’s dependents (including with respect to payment for the costs thereof) than those in effect immediately prior to such termination, which coverage shall become secondary to any coverage provided to Executive by a subsequent employer and to any Medicare coverage for which Executive becomes eligible. After such two-year period, Executive and Executive’s dependents who are qualified beneficiaries shall be entitled, at Executive’s election and cost, to eighteen (18) months of continuation coverage at COBRA rates.

Further, upon Executive’s Disability (irrespective of any termination of employment related thereto), the Company shall pay Executive for twenty-four (24) consecutive months thereafter regular payments in the amount by which the monthly Base Salary exceeds Executive’s monthly Disability insurance benefit.

		
	c.
	Termination By Reason of Death. If Executive’s employment is terminated by reason of Executive’s death, the Company shall pay or provide to Executive’s beneficiaries:

		
	i.
	the Accrued Compensation;

		
	ii.
	the Pro-Rata Bonus; 

		
	iii.
	accelerated vesting, non forfeitability and exercisability, as of the termination date, of the Initial Stock Options and the Initial RSUs as provided for in the equity incentive plan or plans pursuant to which the Initial Stock Options and Initial RSUs were granted; and

		
	iv.
	continued coverage for Executive’s dependents under any health, medical, dental, vision or life insurance program or policy in which Executive was eligible to participate as of 

Exhibit 10.208

the time of Executive’s employment termination, for two (2) years following such termination on terms no less favorable to Executive’s dependents (including with respect to payment for the costs thereof) than those in effect immediately prior to such termination. After such two-year period, Executive’s dependents who are qualified beneficiaries shall be entitled, at their election and cost, to eighteen (18) months of continuation coverage at COBRA rates.

		
	d.
	Termination by the Company Without Cause or by Executive for Good Reason. If Executive’s employment is terminated by the Company without Cause (other than on account of Executive’s death or Disability) or by Executive for Good Reason, in each case during the Employment Term, Executive shall be entitled to the benefits provided in this Section 7(b):  

		
	i.
	the Accrued Compensation;  

		
	ii.
	accelerated vesting, non forfeitability and exercisability, as of the termination date, of the portion of the Initial Stock Options and the Initial RSUs that would have vested had Executive remained employed by the Company for an additional two years following Executive’s termination date, and the Initial Stock Options shall remain exercisable in accordance with its terms;

		
	iii.
	subject to Executive’s compliance with Section 13(g) hereof, a payment equal to two (2) times the sum of Executive’s Base Salary and Target Bonus as in effect immediately prior to Executive’s termination of employment.  Such payment shall be made on the 60th day following the date of Executive’s termination of employment; and

		
	iv.
	subject to Executive’s compliance with Section 13(g) hereof, the Company shall provide Executive and Executive’s dependents with continued coverage under any health or medical insurance program or policy in which Executive was eligible to participate as of the time of Executive’s employment termination, for two (2) years following such termination on terms no less favorable to Executive and Executive’s dependents (including with respect to payment for the costs thereof) than those in effect immediately prior to such termination, which coverage shall become secondary to any coverage provided to Executive by a subsequent employer and to any Medicare coverage for which Executive becomes eligible (provided, 

Exhibit 10.208

however, the parties agree to cooperate such that the continued coverage is, to the extent practicable, provided in a manner so as to minimize adverse tax consequences to the Company under Section 4980D of the Code).  After such two-year period, Executive and Executive’s dependents who are qualified beneficiaries shall be entitled, at Executive’s election and cost, to eighteen (18) months of continuation coverage at COBRA rates. 

		
	e.
	No Mitigation.  Executive shall not be required to mitigate the amount of any payment provided for under this Agreement by seeking other employment or otherwise and no such payment shall be offset or reduced by the amount of any compensation or benefits provided to Executive in any subsequent employment.

		
	f.
	Survival.  The Company’s obligations under this Section 7 shall survive the termination of the Employment Term. 

		
	8.
	Certain Tax Treatment. 

		
	a.
	Golden Parachute Tax.  To the extent that the payments and benefits provided under this Agreement and benefits provided to, or for the benefit of, Executive under any other plan or agreement of the Company or any of its affiliates (such payments or benefits are collectively referred to as the “Payments”) would be subject to the excise tax (the “Excise Tax”) imposed under Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”), the Payments shall be reduced (but not below zero) if and to the extent necessary so that no Payment to be made or benefit to be provided to Executive shall be subject to the Excise Tax (such reduced amount is hereinafter referred to as the “Limited Payment Amount”), but only if such reduction results in a higher after-tax payment to Executive after taking into account the Excise Tax and any additional taxes Executive would pay if such payments and benefits were not reduced. If applicable, the Company shall reduce or eliminate the payments provided under Section 7(c)(ii) or 7(c)(iii), as applicable, to effect the provisions of this Section 8 (with payments not subject to Section 40A of the Code being reduced first).  The determination of whether the Payments shall be reduced to the Limited Payment Amount pursuant to this Agreement and the amount of such Limited Payment Amount shall be made, at the Company’s expense, by a reputable accounting firm selected by Executive and reasonably acceptable to the Company (the “Accounting Firm”). The Accounting Firm shall provide its determination (the “Determination”), together with detailed supporting calculations and documentation to the Company and Executive within ten (10) days of the date of termination, if applicable, or such other time as specified by mutual agreement of the Company and Executive, and 

Exhibit 10.208

if the Accounting Firm determines that no Excise Tax is payable by Executive with respect to the Payments, it shall furnish Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to any such Payments. The Determination shall be binding, final and conclusive upon the Company and Executive.      

		
	b.
	Section 409A.  The parties intend for the payments and benefits under this Agreement to be exempt from Section 409A of the Code or, if not so exempt, to be paid or provided in a manner which complies with the requirements of such section, and intend that this Agreement shall be construed and administered in accordance with such intention.  Notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and/or tax penalties under Section 409A of the Code, (i) no amounts shall be paid to Executive under Section 7 of this Agreement until Executive would be considered to have incurred a “separation from service” from the Company within the meaning of Section 409A of the Code, (ii) amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Agreement during the six-month period immediately following Executive’s separation from service shall instead be paid on the first business day after the date that is six months following Executive’s separation from service (or death, if earlier), (iii) each amount to be paid or benefit to be provided under this Agreement shall be construed as a separately identified payment for purposes of section 409A of the Code, (iv) any payments that are due within the “short term deferral period” as defined in section 409A of the Code shall not be treated as deferred compensation unless applicable law requires otherwise and (v) amounts reimbursable to Executive under this Agreement shall be paid to Executive on or before the last day of the year following the year in which the expense was incurred and the amount of expenses eligible for reimbursement (and in-kind benefits provided to Executive) during any one year may not effect amounts reimbursable or provided in any subsequent year. 

		
	9.
	Records and Confidential Data.

		
	a.
	Executive acknowledges that in connection with the performance of Executive’s duties during the Employment Term, the Company and its affiliates will make available to Executive, or Executive will develop and have access to, certain Confidential Information (as defined below) of the Company and its affiliates. Executive acknowledges and agrees that any and all Confidential Information learned or obtained by Executive during the course of Executive’s employment by the Company or otherwise, whether developed by Executive alone or in conjunction with others or otherwise, shall be 

Exhibit 10.208

and is the property of the Company and its affiliates. 

		
	b.
	Confidential Information will be kept confidential by Executive, will not be used in any manner that is detrimental to the Company or its affiliates, will not be used other than in connection with Executive’s discharge of Executive’s duties hereunder, and will be safeguarded by Executive from unauthorized disclosure; provided, however, that Confidential Information may be disclosed by Executive (v) to the Company and its affiliates, or to any authorized agent or representative of any of them, (w) in connection with performing his duties hereunder, (x) when required to do so by law or by a court, governmental agency, legislative body, arbitrator or other person with apparent jurisdiction to order him to divulge, disclose or make accessible such information, provided that Executive notify the Company prior to such disclosure, (y) in the course of any proceeding under Sections 12 or 13 of this Agreement or (z) in confidence to an attorney or other professional advisor for the purpose of securing professional advice, so long as such attorney or advisor is subject to confidentiality restrictions no less restrictive than those applicable to Executive hereunder. 

		
	c.
	Following the termination of Executive’s employment hereunder, as soon as possible after the Company’s written request, Executive will return to the Company all written Confidential Information that is in his possession or control and Executive will destroy all of his copies of any analyses, compilations, studies or other documents prepared by Executive or for Executive’s use containing or reflecting any Confidential Information. Within five (5) business days of the receipt of such request by Executive, Executive shall, upon written request of the Company, deliver to the Company a document certifying that such written Confidential Information has been returned or destroyed in accordance with this Section 10(c). 

		
	d.
	For the purposes of this Agreement, “Confidential Information” shall mean all confidential and proprietary information of the Company and its affiliates, including, without limitation,

		
	i.
	trade secrets concerning the business and affairs of the Company and its affiliates, product specifications, data, know-how, formulae, compositions, processes, non-public patent applications, designs, sketches, photographs, graphs, drawings, samples, inventions and ideas, past, current, and planned research and development, current and planned manufacturing or distribution methods and processes, customer lists, current and anticipated customer requirements, price lists, market studies, business plans, computer software and programs (including object code and source code), computer software and database technologies, 

Exhibit 10.208

systems, structures, and architectures (and related formulae, compositions, processes, improvements, devices, know-how, inventions, discoveries, concepts, ideas, designs, methods and information);

		
	ii.
	information concerning the business and affairs of the Company and its affiliates (which includes unpublished financial statements, financial projections and budgets, unpublished and projected sales, capital spending budgets and plans, the names and backgrounds of key personnel, to the extent not publicly known, personnel training and techniques and materials) however documented; and

		
	iii.
	notes, analysis, compilations, studies, summaries, and other material prepared by or for the Company or its affiliates containing or based, in whole or in part, on any information included in the foregoing.  For purposes of this Agreement, the Confidential Information shall not include and Executive’s obligation’s shall not extend to (i) information that is generally available to the public, (ii) information obtained by Executive other than pursuant to or in connection with this employment and (iii) information that is required to be disclosed by law or legal process.   

		
	e.
	Nothing herein or elsewhere shall preclude Executive from retaining and using (i) his personal papers and other materials of a personal nature, including, without limitation, photographs, correspondence, personal diaries, calendars, personal files, rolodex (and paper/electronic equivalents) and phone books (so long as no such materials are covered by any Company hold order), (ii) documents relating to his personal entitlements and obligations, and (iii) information that is necessary for his personal tax purposes.   

		
	10.
	Covenant Not to Solicit, Not to Compete, Not to Disparage and to Cooperate in Litigation.

		
	a.
	Covenant Not to Solicit.  To protect the Confidential Information and other trade secrets of the Company and its affiliates as well as the goodwill and competitive business of the Company and its affiliates, Executive agrees, during the Employment Term and for a period of eighteen (18) months after Executive’s cessation of employment with the Company, not to solicit or participate in or assist in any way in the solicitation of any employees of the Company or its affiliates.  For purposes of this covenant, “solicit” or “solicitation” means directly or indirectly influencing or attempting to influence employees of the Company or its affiliates to cease employment 

Exhibit 10.208

with the Company and its affiliates (except in the course of Executive’s duties to the Company) or to become employed with any other person, partnership, firm, corporation or other entity. Executive agrees that the covenants contained in this Section 11(a) are reasonable and desirable to protect the Confidential Information of the Company and its affiliates, provided, that solicitation through general advertising not targeted at the Company’s or its affiliates’ employees or the provision of references shall not constitute a breach of such obligations. 

		
	b.
	Covenant Not to Compete.  

		
	i.
	To protect the Confidential Information and other trade secrets of the Company and its affiliates as well as the goodwill and competitive business of the Company and its affiliates, Executive agrees, during the Employment Term and for a period of eighteen (18) months after Executive’s cessation of employment with the Company, that Executive will not, except in the course of Executive’s employment hereunder, directly or indirectly manage, operate, control, or participate in the management, operation, or control of, be employed by, associated with, or in any manner connected with, lend Executive’s name to, or render services or advice to, any third party, or any business, whose business competes with the medical devices business of the Company and its affiliates during the twelve (12) month period ending on the date of the cessation of Executive’s employment with the Company); provided, however, that Executive may in any event (w) own up to a 5% passive ownership interest in any public or private entity, (x) be employed by, or otherwise have material association with, any business that competes with the medical devices business of the Company and its affiliates so long as his employment or association is with a separately managed and operated division or affiliate of such business that does not compete with the Company and its affiliates, and (y) serve on the board of any business that competes with the medical devices business of the Company and its affiliates as an immaterial part of its overall business, provided that he recuses himself fully and completely from all matters relating to such business. 

		
	ii.
	For purposes of this Section 11(b), any third party, or any business, whose that competes includes any entity with which the Company has a product(s) licensing agreement relating to the medical devices business of the Company at the date of the cessation of Executive’s employment with the Company and any entity with which the Company is, as 

Exhibit 10.208

of the date of the cessation of Executive’s employment with the Company, to the knowledge of Executive (as reflected by the deliberations of the Company’s senior leadership team), negotiating, and eventually concludes within twelve (12) months of the Employment Term, a product licensing or acquisition agreement relating to the medical devices business.   

		
	c.
	Nondisparagement.  Executive covenants that during and following the Employment Term, Executive will not disparage or encourage or induce others to disparage the Company or its affiliates, together with all of their respective past and present directors and officers, as well as their respective past and present managers, officers, shareholders, partners, employees, agents, attorneys, servants and customers and each of their predecessors, successors and assigns (collectively, the “Company Entities and Persons”); provided that such limitation shall extend to past and present managers, officers, shareholders, partners, employees, agents, attorneys, servants and customers only in their capacities as such or in respect of their relationship with the Company and its affiliates.  The term “disparage” includes, without limitation, comments or statements adversely affecting in any manner (i) the conduct of the business of the Company Entities and Persons, or (ii) the business reputation of the Company Entities and Persons.  Nothing in this Agreement is intended to or shall prevent either party from providing, or limiting testimony in response to a valid subpoena, court order, regulatory request or other judicial, administrative or legal process or otherwise as required by law, or in arbitration under Section 13. 

		
	d.
	Cooperation in Any Investigations and Litigation.  Executive agrees that Executive will reasonably cooperate with the Company and its affiliates, and its counsel, in connection with any investigation, inquiry, administrative proceeding or litigation relating to any matter in which Executive becomes involved or of which Executive has knowledge as a result of Executive’s service with the Company by providing truthful information.  The Company agrees to promptly reimburse Executive for reasonable expenses (including travel expenses, attorneys’ fees and other expenses of counsel) incurred by Executive, in connection with Executive’s cooperation pursuant to this Section 11(d).  Such reimbursements shall be made within sixty (60) days following Executive’s submission of a written invoice to the Company describing such expenses in reasonable detail, and in no event later than the calendar year following the year in which the expenses are incurred.  Executive agrees that, in the event Executive is subpoenaed by any person or entity (including, but not limited to, any government agency) to give testimony (in a deposition, court proceeding or otherwise) which in any way relates to Executive’s employment by the Company, Executive will, to the extent not 

Exhibit 10.208

legally prohibited from doing so, give prompt notice of such request to the Chief Legal Officer of Endo so that the Company may contest the right of the requesting person or entity to such disclosure before making such disclosure.  Nothing in this provision shall require Executive to violate Executive’s obligation to comply with valid legal process. 

		
	e.
	Blue Pencil.  It is the intent and desire of Executive and the Company that the provisions of this Section 11 be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is sought. If any particular provision of this Section 11 shall be determined to be invalid or unenforceable, such covenant shall be amended, without any action on the part of either party hereto, to delete therefrom the portion so determined to be invalid or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made. 

		
	f.
	Survival.  Executive’s obligations under this Section 11 shall survive the termination of the Employment Term. 

		
	11.
	Remedies for Breach of Obligations under Sections 10 or 11 hereof.  Executive acknowledges that the Company and its affiliates will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if Executive breaches Executive’s obligations under Sections 10 or 11 hereof. Accordingly, Executive agrees that the Company and its affiliates will be entitled, in addition to any other available remedies, to obtain injunctive relief against any breach or prospective breach by Executive of Executive’s obligations under Sections 10 or 11 hereof in any Federal or state court sitting in the State of Delaware, or, at the Company’s election, in any other state in which Executive maintains Executive’s principal residence or Executive’s principal place of business.  Executive hereby submits to the non-exclusive jurisdiction of all those courts for the purposes of any actions or proceedings instituted by the Company or its affiliates to obtain that injunctive relief, and Executive agrees that process in any or all of those actions or proceedings may be served by registered mail, addressed to the last address provided by Executive to the Company, or in any other manner authorized by law.   

		
	12.
	Representations and Warranties.

		
	a.
	The Company represents and warrants that (i) it is fully authorized to enter into this Agreement and to perform its obligations under it, (ii) the execution, delivery and performance of this Agreement by it does not violate any applicable law, regulation, order, judgment or decree or any agreement, arrangement, plan or corporate governance document (x) to which it is a party or (y) by which it is bound, and 

Exhibit 10.208

(iii) upon the execution and delivery of this Agreement by the parties, this Agreement shall be its valid and binding obligation, enforceable against it in accordance with its terms, except to the extent that enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting the enforcement of creditors’ rights generally. 

		
	b.
	Executive represents and warrants to the Company that the execution and delivery by Executive of this Agreement do not, and the performance by Executive of Executive's obligations hereunder will not, with or without the giving of notice or the passage of time, or both: (a) violate any judgment, writ, injunction, or order of any court, arbitrator, or governmental agency applicable to Executive; or (b) conflict with, result in the breach of any provisions of or the termination of, or constitute a default under, any agreement to which Executive is a party or by which Executive is or may be bound.  

		
	13.
	Miscellaneous.

		
	a.
	Successors and Assigns.

		
	i.
	This Agreement shall be binding upon and shall inure to the benefit of the Company, its successors and permitted assigns and the Company shall require any successor or assign to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession or assignment had taken place. The Company may not assign or delegate any rights or obligations hereunder except to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company or to an affiliate of the Company. The term “the Company” as used herein shall include a corporation or other entity acquiring all or substantially all the assets and business of the Company (including this Agreement) whether by operation of law or otherwise. 

		
	ii.
	Neither this Agreement nor any right or interest hereunder shall be assignable or transferable by Executive, Executive’s beneficiaries or legal representatives, except by will or by the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by Executive’s legal personal representatives. 

		
	b.
	Fees and Expenses. The Company shall pay reasonable and documented legal fees and related expenses, up to a maximum amount of $10,000, incurred by Executive in connection with the 

Exhibit 10.208

negotiation of this Agreement. Such reimbursement shall be made as soon as practicable, but in no event later than the end of the calendar year following the calendar year in which the expenses were incurred.

		
	c.
	Indemnification.  Executive shall be indemnified by the Company as, and to the extent, provided in by-laws and Certificate of Incorporation of the Company and Endo.  The obligations under this paragraph shall survive termination of the Employment Term. 

		
	d.
	Right to Counsel.  Executive acknowledges that Executive has had the opportunity to consult with legal counsel of Executive’s choice in connection with the drafting, negotiation and execution of this Agreement and related employment arrangements. 

		
	e.
	Notice. For the purposes of this Agreement, notices and all other communications provided for in the Agreement (including the Notice of Termination) shall be in writing and shall be deemed to have been duly given when personally delivered or sent by Certified mail, return receipt requested, postage prepaid, addressed to the respective addresses last given by each party to the other, provided that all notices to the Company shall be directed to the attention of the Chief Legal Officer of Endo. All notices and communications shall be deemed to have been received on the date of delivery thereof or on the third business day after the mailing thereof, except that notice of change of address shall be effective only upon receipt. 

		
	f.
	Withholding. The Company shall be entitled to withhold the amount, if any, of all taxes of any applicable jurisdiction required to be withheld by an employer with respect to any amount paid to Executive hereunder. The Company, in its sole and absolute discretion, shall make all determinations as to whether it is obligated to withhold any taxes hereunder and the amount hereof. 

		
	g.
	Release of Claims. The termination benefits described in Section 7(b)(ii) and (iii) of this Agreement shall be conditioned on Executive delivering to the Company, a signed release of claims in the form of Exhibit C hereto within forty-five (45) days or twenty-one (21) days, as may be applicable under the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection Act, following Executive’s termination date, and not revoking Executive’s consent to such release of claims within seven (7) days of such execution; provided, however, that Executive shall not be required to release any rights Executive may have to be indemnified by the Company or Endo under Section 14(b) of this Agreement or under any other indemnification agreement entered into between Executive and the Company. 

Exhibit 10.208

		
	h.
	Modification. No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by Executive and the Company. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. No agreement or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement. 

		
	i.
	Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware applicable to contracts executed in and to be performed entirely within such State, without giving effect to the conflict of law principles thereof. 

		
	j.
	Inconsistencies.  In the event of any inconsistency between any provision of this Agreement and any provision of any employee handbook, personnel manual, program, policy, or arrangement of the Company or its affiliates (including, without limitation, any provisions relating to notice requirements and post-employment restrictions), the provisions of this Agreement shall control, unless Executive otherwise agrees in a writing that expressly refers to the provision of this Agreement whose control he is waiving. 

		
	k.
	Beneficiaries/References.  In the event of Executive’s death or a judicial determination of his incompetence, references in this Agreement to Executive shall be deemed, where appropriate, to refer to his beneficiary, estate or other legal representative. 

		
	l.
	Survivorship.  Except as otherwise set forth in this Agreement, the respective rights and obligations of the parties hereunder shall survive the Employment Term and any termination of Executive’s employment.  Without limiting the generality of the forgoing, the provisions of Section 7, 10, 11, and 12 shall survive the Employment Term. 

		
	m.
	Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. 

		
	n.
	Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto and supersedes all prior agreements, if any, understandings and arrangements, oral or written, between the parties hereto with respect to the subject matter hereof. 

Exhibit 10.208

		
	o.
	Counterparts.  This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement.

Exhibit 10.208

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer and Executive has executed this Agreement as of the day and year first above written.

	
	
	AMERICAN MEDICAL SYSTEMS, INC.

	
		
	By:
	 /s/  David P. Holveck 

	Name:
	David P. Holveck

	Title:
	Chief Executive Officer

	
	
	EXECUTIVE

	
		
	By:
	/s/ Camille Farhat

	Name:
	Camille Farhat

Exhibit 10.208

EXHIBIT A

FORM OF OPTION AGREEMENT

ENDO HEALTH SOLUTIONS, INC.
2010 STOCK INCENTIVE PLAN STOCK OPTION AGREEMENT

This Stock Option Agreement (the "Option Agreement") is made and entered into as of the date of grant set forth below (the "Date of Grant") by and between Endo Health Solutions, Inc., a Delaware corporation (the "Company"), and the optionee named below (the "Optionee").  Capitalized terms not defined herein shall have the meaning ascribed to them in the Company's 2010 Stock Incentive Plan (the "Plan").
Name of Optionee:    
Social Security No.:    

Address:

Shares Subject to
Option:
 

Exercise Price Per
Share:
 

Exhibit 10.208

Date of Grant:    

Expiration Date:    

Vesting Dates:    25% of the Option Shares on first anniversary of Date of Grant
25% of the Option Shares on second anniversary of Date of Grant
25% of the Option Shares on third anniversary of Date of Grant
25% of the Option Shares on fourth anniversary of Date of Grant

Classification of Option
(Check one):            Incentive Stock Option
X      Non-Qualified Stock Option

1.          Number of Shares.  The Company hereby grants to the Grantee an option (the "Option") to purchase the total number of shares of Company Stock set forth above as Shares Subject to  Option (the "Option  Shares") at the  Exercise Price Per Share set  forth  above (the "Exercise Price"), subject to all of the terms and conditions of this Option Agreement and the Plan.

2.          Incorporation of Plan.  The Plan is hereby incorporated by reference and made a part hereof, and the Option and this Option Agreement shall be subject to all terms and conditions of the Plan.

3.          Option Term.  The term of the Option and of this Option Agreement (the "Option Term") shall commence on the Date of Grant set forth above and, unless previously terminated pursuant to Section 7 of the Plan or Paragraph 4 of this Option Agreement, shall terminate upon the Expiration Date set forth above.  As of the Expiration Date, all rights of the Optionee hereunder shall terminate.

4.           Termination   of   Employment.   Unless otherwise provided in an individual agreement with the Optionee, upon   termination   of   the   Optionee's employment, the Option shall be treated in accordance with Section 7 of the Plan;

5.          Vesting.  Except as provided in Section 7 of the Plan or Paragraph 4 above, the Option shall become exercisable with respect to the number of Option Shares specified on the Exercisability Dates set forth above. Once exercisable, the Option shall continue to be exercisable at any time or times prior to the Expiration Date, subject to the provisions hereof and of the Plan.

6.           Authority of the Committee.  The Committee shall have full authority to interpret and construe the terms of the Plan and this Option Agreement.  

Exhibit 10.208

The determination of the Committee as to any such matter of interpretation or construction shall be final, binding and conclusive.

7.          Notices.  All notices and other communications under this Agreement shall be in writing and shall be given by first class mail, certified or registered with return receipt requested, and shall be deemed to have been duly given three days after mailing to the respective parties named below:

If to Company:    Endo Health Solutions, Inc.
100 Endo Boulevard
Chadds Ford, PA 19317
Attention: Treasurer

If to the Participant:    At the address noted above.

Either party hereto may change such party's address for notices by notice duly given pursuant hereto.

8.          Amendments. This Option Agreement may be amended or modified at any time only by an instrument in writing signed by each of the parties hereto.

9.          Governing Law. This Option Agreement shall be governed by and construed according to the laws of the State of Delaware without regard to its principles of conflict of laws.

10.        Acceptance.  The Optionee hereby acknowledges receipt of a copy of the Plan and this Option Agreement.  The Optionee has read and understand the terms and provision thereof, and  accepts  the  Option  subject  to  all  the  terms  and  conditions  of  the  Plan and  this Agreement.

Exhibit 10.208

IN WITNESS WHEREOF, the parties hereto have executed and delivered this Option Agreement on the day and year first above written.

	
	
	ENDO HEALTH SOLUTIONS, INC. 

	
		
	By:
	 

	Name:
	David P. Holveck

	Title:
	President & Chief Executive Officer

	Officer

	
	
	Optionee

Exhibit 10.208

EXHIBIT B

FORM OF RESTRICTED STOCK UNIT AGREEMENT

ENDO HEALTH SOLUTIONS, INC.
ENDO STOCK AWARD AGREEMENT UNDER THE 2010 STOCK INCENTIVE PLAN

This Endo Stock Award Agreement (this "Award  Agreement"),  is made and entered into  as  of  the  date  of  grant  set  forth   below  (the  "Date   of  Grant")   by  and  between Endo Health Solutions, Inc., a Delaware corporation (the "Company"), and the participant named below (the "Participant").  Capitalized terms not defined herein shall have the meanings ascribed to them in the Endo Health Solutions, Inc. 2010 Stock Incentive Plan (the "Plan").   Where the context permits, references to the Company shall include any successor to the Company.

Name of Participant:    
Social Security No.:     
Address:     

Number of Endo Stock Awards:     

Date of Grant:     

Vesting Dates:

25% of the Endo Stock Awards on first anniversary of Date of Grant
25% of the Endo Stock Awards on second anniversary of Date of Grant
25% of the Endo Stock Awards on third anniversary of Date of Grant
25% of the Endo Stock Awards on fourth anniversary of Date of Grant

1.    Grant of Endo Stock Awards.  The Company hereby grants to the Participant the total number "Endo" restricted stock units set forth above (the "Endo Stock Awards"), subject to all of the terms and conditions of this Award Agreement and the Plan.

2.    Form of Payment and Vesting.  Each Endo Stock Award granted hereunder shall represent the right to receive (1) one share of Company Stock as of the date of vesting.  Except as provided in Section 7 of the Plan or Paragraph 4 of this Award Agreement, such vesting shall occur on the vesting dates set forth above, 

Exhibit 10.208

provided that the Participant is employed by the Company on  the applicable  vesting  date.   Notwithstanding the above,  a share  of  Company  Stock  shall  be treated as delivered on the applicable vesting date provided that it is delivered on a date following the vesting date that is in the same calendar year as the vesting date or, if later, by the fifteenth day of the third calendar month following the vesting date.

3.    Restrictions.

(a)   The Endo Stock Awards - granted hereunder may not be sold, assigned, transferred, pledged, hypothecated or otherwise disposed of or encumbered, and shall be subject to a risk of forfeiture and  until any additional requirements or restrictions contained  in this A ward Agreement or in the Plan have been otherwise satisfied, terminated or expressly waived by the Company in writing.

(b)  Except as provided in Section 4, upon vesting of the Endo Stock Awards, the shares subject to the Endo Stock Awards shall be issued hereunder (provided that such issuance is otherwise in accordance with federal and state securities laws) as soon as practicable thereafter, but in any event no later than the end of the taxable year in which such vesting occurs or, if later, by the 15th day of the third calendar month following the vesting date.

4.     Termination of Employment Services; Disability.  Unless otherwise provided in an individual agreement with the Participant,

(a)  Termination of Employment For Cause.  Upon the Participant's termination of employment with the Company and its Subsidiaries for Cause all of the Participant's unvested Endo Stock Awards shall be forfeited as of such date.

(b)        Termination of Employment on Account of Death.  Upon termination of the Participant's employment on account of death, all of the Participant's  unvested Endo Stock A wards shall vest immediately.

(c)  Termination of Employment on Account of Voluntary Retirement with Consent of Company.  If a Participant voluntarily Retires with the consent of the Company, all of the Participant's unvested Endo Stock Awards as of date of termination shall continue to vest in accordance with the original vesting schedule set forth in Section 2 of this Award Agreement.

(d)  Termination of Employment for any Other Reason.   If the Participant has a termination of employment for any reason other than the reasons enumerated in paragraphs (a) through (d) above, Endo Stock Awards that are unvested as of date of termination shall be forfeited.

(e)  Disability.   Upon termination of the Participant's employment on account of “disability” (as defined, notwithstanding anything to the contrary in the Plan, within the meaning of Section 409A), all of the Participant's  unvested Endo Stock A wards shall vest immediately.

Exhibit 10.208

5.    No Shareholder Rights Prior to Vesting. The Participant shall have no rights of a shareholder (including the right to distributions or dividends) until shares of Company Stock are issued pursuant to the terms of this Award Agreement.

6.    Endo Stock Award (RSU) Agreement Subject to Plan.   This Award Agreement is made pursuant to all of the provisions of the Plan, which is incorporated herein by this reference, and is intended, and shall be interpreted in a manner, to comply therewith. In the event of any conflict between the provisions of this Award Agreement and the provisions of the Plan, the provisions of the Plan shall govern.

7.    No Rights to Continuation of Employment. Nothing in the Plan or this Award Agreement shall confer upon the Participant any right to continue in the employ of the Company or any Subsidiary thereof or shall interfere with or restrict the right of the Company or its shareholders (or of a Subsidiary or its shareholders, as the case may be) to terminate the Participant's employment any time for any reason whatsoever, with or without cause.

8.    Tax Withholding. The Company shall be entitled to require a cash payment by or on behalf of the Participant and/or to deduct from other Endo Stock Awards granted hereunder of compensation payable to the Participant any sums required by federal, state or local tax law to be withheld or to satisfy any applicable payroll deductions with respect to the vesting of, lapse of restrictions on, or payment of any Endo Stock Award.

9.    Section 409A Compliance.  The Endo Stock Award is intended to comply with Code Section 409A to the extent subject thereto and shall be interpreted in accordance with Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Date of Grant.  Notwithstanding any provision in the Plan or Award Agreement to the contrary, no  payment or  distribution  under this  Award  Agreement that constitutes an  item of deferred  compensation  under  Code   Section  409A  and  becomes  payable  by  reason  ofthe Participant's  termination  of  employment  or  service  with  the  Company  will  be  made  to the Participant until the Participant's  termination of employment or service constitutes a "separation from service" (as defined in Code Section 409A).  For purposes of this Award Agreement, each amount to be paid or benefit to be provided shall be construed as a separate identified payment for purposes of Code Section 409A.  If a participant is a "specified employee" (as defined in Code Section 409A), then to the extent necessary to avoid the imposition of taxes under Code Section 409A, such Participant shall not be entitled to any payments upon a termination of his or her employment or service until the earlier of:  (i) the expiration of the six (6)-month period measured from the date of such Participant's "separation from service" or (ii) the date of such Participant's death.  Upon the expiration of the applicable waiting period set forth in the preceding sentence, all payments and benefits deferred pursuant to this Section 9 (whether they would have otherwise been payable in a single lump sum or in installments in the absence of such deferral) shall be paid to such Participant in a lump sum as soon as practicable, but in no event later than sixty (60) calendar days, 

Exhibit 10.208

following such expired period, and any remaining payments due under this Award Agreement will be paid in accordance with the normal payment dates specified for them herein.

10.    Governing Law.  This Award Agreement shall be governed by, interpreted under, and construed and enforced in accordance with the internal laws, and not the laws pertaining to conflicts or choices of laws, of the State of Delaware applicable to agreements made and to be performed wholly within the State of Delaware.

11.    Binding on Successors. The terms of this Award Agreement shall be binding upon the Participant and upon the Participant's heirs, executors, administrators, personal representatives, transferees, assignees and successors in interest, and upon the Company and its successors and assignees, subject to the terms of the Plan.

12.    No Assignment.  Notwithstanding anything to the contrary in this Award Agreement, neither this Award Agreement nor any rights granted herein shall be assignable by the Participant.

13.    Necessary Acts.  The Participant hereby agrees to perform all acts, and to execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Award Agreement, including but not limited to all acts and documents related to compliance with federal and/or state securities and/or tax laws.

14.    Entire Endo Stock Award (RSU) Agreement. This Award Agreement and the Plan contain the entire agreement and understanding among the parties as to the subject matter hereof.

15.    Headings.  Headings are used solely for the convenience of the parties and shall not be deemed to be a limitation upon or descriptive of the contents of any such Section.

16.    Counterparts.  This Award Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.

17.    Notices. All notices and other communications under this Agreement shall be in writing and shall be given by first class mail, certified or registered with return receipt requested, and shall be deemed to have been duly given three days after mailing to the respective parties named below:

If to Company:    Endo Health Solutions, Inc.
100 Endo Boulevard
Chadds Ford, PA 19317
Attention: Treasurer

Exhibit 10.208

If to the Participant:    At the address noted above.

Either party hereto may change such party's address for notices by notice duly given pursuant hereto.

18.    Amendment.  No amendment or modification hereof shall be valid unless it shall be in writing and signed by all parties hereto.

19.    Acceptance.  The Participant hereby acknowledges receipt of a copy of the Plan and this Award Agreement.  The Participant has read and understand the terms and provision thereof, and accepts the Endo Stock Awards subject to all the terms and conditions of the Plan and this Award Agreement.

IN WITNESS WHEREOF, the parties hereto have executed this Award Agreement as of the date set forth above.

	
	
	ENDO HEALTH SOLUTIONS, INC. 

	
		
	By:
	 

	Name:
	David P. Holveck

	Title:
	President & Chief Executive Officer

	
	
	Participant

Exhibit 10.208

EXHIBIT C

FORM OF RELEASE AGREEMENT

THIS RELEASE AGREEMENT (the “Release”) is made by and between Camille Farhat (“Executive”) and American Medical Systems, Inc. (the “Company”).  

		
	1.
	FOR AND IN CONSIDERATION of the payments and benefits provided in the Employment Agreement between Executive and the Company dated as of ________, 2012, (the “Employment Agreement”), Executive, for himself or herself, his or her successors and assigns, executors and administrators, now and forever hereby releases and discharges the Company, together with all of its past and present parents, subsidiaries, and affiliates, together with each of their officers, directors, stockholders, partners, employees, agents, representatives and attorneys, and each of their subsidiaries, affiliates, estates, predecessors, successors, and assigns (hereinafter collectively referred to as the “Releasees”) from any and all rights, claims, charges, actions, causes of action, complaints, sums of money, suits, debts, covenants, contracts, agreements, promises, obligations, damages, demands or liabilities of every kind whatsoever, in law or in equity, whether known or unknown, suspected or unsuspected, which Executive or Executive’s executors, administrators, successors or assigns ever had, now has or may hereafter claim to have by reason of any matter, cause or thing whatsoever; arising from the beginning of time up to the date of the Release: (i) relating in any way to Executive’s employment relationship with the Company or any of the Releasees, or the termination of Executive’s employment relationship with the Company or any of the Releasees; (ii) arising under or relating to the Employment Agreement; (iii) arising under any federal, local or state statute or regulation, including, without limitation, the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection Act, Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act of 1990, the Employee Retirement Income Security Act of 1974, and/or the applicable state law against discrimination, each as amended; (iv) relating to wrongful employment termination or breach of contract; or (v) arising under or relating to any policy, agreement, understanding or promise, written or oral, formal or informal, between the Company and any of the Releasees and Executive; provided, however, that notwithstanding the foregoing, nothing contained in the Release shall in any way diminish or impair:  (a) any rights Executive may have, from and after the date the Release is executed; (b) any rights to indemnification that may exist from time to time under the Company’s certificate of incorporation or bylaws, or state law or under any other indemnification agreement entered into between Executive and the Company; (c) any rights Executive may have that arise under (or that are preserved by) the Employment Agreement; (d) Executive’s ability to bring appropriate proceedings to enforce the Release; (e) any rights or claims Executive may have that cannot be waived under applicable law; (f) any claim against any Releasee that brings a claim against Executive (collectively, the “Excluded Claims”).  Executive further acknowledges and agrees that, except with respect to Excluded Claims, the Company and the Releasees have fully 

Exhibit 10.208

satisfied any and all obligations whatsoever owed to Executive arising out of Executive’s employment with the Company or any of the Releasees, and that no further payments or benefits are owed to Executive by the Company or any of the Releasees.

		
	2.
	Executive understands and agrees that, except for the Excluded Claims, Executive has knowingly relinquished, waived and forever released any and all rights to any personal recovery in any action or proceeding that may be commenced on Executive’s behalf arising out of the aforesaid employment relationship or the termination thereof, including, without limitation, claims for back pay, front pay, liquidated damages, compensatory damages, general damages, special damages, punitive damages, exemplary damages, costs, expenses and attorneys’ fees.

		
	3.
	Executive acknowledges and agrees that Executive has been advised to consult with an attorney of Executive’s choosing prior to signing the Release.  Executive understands and agrees that Executive has the right and has been given the opportunity to review the Release with an attorney of Executive’s choice should Executive so desire.  Executive also agrees that Executive has entered into the Release freely and voluntarily. Executive further acknowledges and agrees that Executive has had at least [twenty-one (21)] [forty-five (45)] calendar days to consider the Release, although Executive may sign it sooner if Executive wishes.  In addition, once Executive has signed the Release, Executive shall have seven (7) additional days from the date of execution to revoke Executive’s consent and may do so by writing to:  ___________.  The Release shall not be effective, and no payments shall be due hereunder, earlier than the eighth (8th) day after Executive shall have executed the Release and returned it to the Company, assuming that Executive had not revoked Executive’s consent to the Release prior to such date.  

		
	4.
	It is understood and agreed by Executive that the payment made to Executive is not to be construed as an admission of any liability whatsoever on the part of the Company or any of the other Releasees, by whom liability is expressly denied.

		
	5.
	The Release is executed by Executive voluntarily and is not based upon any representations or statements of any kind made by the Company or any of the other Releasees as to the merits, legal liabilities or value of Executive’s claims.  Executive further acknowledges that Executive has had a full and reasonable opportunity to consider the Release and that Executive has not been pressured or in any way coerced into executing the Release.

		
	6.
	The exclusive venue for any disputes arising hereunder shall be the state or federal courts located in the State of Delaware, and each of the parties hereto irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of the venue of any such proceeding brought in such a court and any claim that any such proceeding brought in such a court has been brought in an inconvenient forum.  Each of the parties hereto also agrees that any final and unappealable judgment against a party hereto in connection with any action, suit or other proceeding may be enforced in any court 

Exhibit 10.208

of competent jurisdiction, either within or outside of the United States.  A certified or exemplified copy of such award or judgment shall be conclusive evidence of the fact and amount of such award or judgment.

		
	7.
	The Release and the rights and obligations of the parties hereto shall be governed and construed in accordance with the laws of the State of Delaware.  If any provision hereof is unenforceable or is held to be unenforceable, such provision shall be fully severable, and this document and its terms shall be construed and enforced as if such unenforceable provision had never comprised a part hereof, the remaining provisions hereof shall remain in full force and effect, and the court construing the provisions shall add as a part hereof a provision as similar in terms and effect to such unenforceable provision as may be enforceable, in lieu of the unenforceable provision.

		
	8.
	The Release shall inure to the benefit of and be binding upon the Company and its successors and assigns.  

IN WITNESS WHEREOF, Executive and the Company have executed the Release as of the date and year first written above. 

IMPORTANT NOTICE:  BY SIGNING BELOW YOU RELEASE AND GIVE UP ANY AND ALL LEGAL CLAIMS, KNOWN AND UNKNOWN, THAT YOU MAY HAVE AGAINST THE COMPANY AND RELATED PARTIES.

	
					
	AMERICAN MEDICAL SYSTEMS, INC.
	 
	CAMILLE FARHAT

	.

	 
	 
	 

	Dated:
	 
	 
	Dated:Ex. 10.209 Supplemental Indenture 5.375% 2023

Exhibit 10.209

SUPPLEMENTAL INDENTURE
SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of December 22, 2014, among Boca Pharmacal, LLC, a Florida limited liability company, DAVA International, LLC, a Delaware limited liability company and DAVA Capital Management, Inc., a Delaware corporation (collectively, the “Guaranteeing Subsidiaries”), subsidiaries of Endo Limited, a private limited company incorporated under the laws of Ireland (the “Company”), the Issuers, the other Guarantors (both, as defined in the Indenture referred to below) and Wells Fargo Bank, National Association, as trustee under the Indenture referred to below (the “Trustee”).
W I T N E S S E T H
WHEREAS, Endo Finance LLC, a Delaware limited liability company, and Endo Finco Inc., a Delaware corporation, have heretofore executed and delivered to the Trustee an indenture, dated as of June 30, 2014, as supplemented by a supplemental indenture, dated as of July 10, 2014, and a supplemental indenture, dated as of August 11, 2014, in each case, among the Issuers, the Guarantors party thereto and the Trustee (the “Indenture”), providing for the issuance of 5.375% Senior Notes due 2023 (the “Notes”);
WHEREAS, the Indenture provides that under certain circumstances the Guaranteeing Subsidiaries shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiaries shall unconditionally guarantee all of the Issuers’ Obligations under the Notes and the Indenture on the terms and conditions set forth herein (the “Note Guarantee”); 
WHEREAS, this Supplemental Indenture has not resulted in a material modification of the Notes for Foreign Account Tax Compliance Act purposes; and
WHEREAS, pursuant to Section 9.01 of the Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture.
NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Guaranteeing Subsidiaries and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows:
1.    CAPITALIZED TERMS.  Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.
2.    AGREEMENT TO GUARANTEE.  Each of the Guaranteeing Subsidiaries hereby agrees to provide an unconditional Guarantee on the terms and subject to the conditions set forth in the Note Guarantee and in the Indenture including but not limited to Article 10 thereof.
3.    NO RECOURSE AGAINST OTHERS.  No director, officer, employee, incorporator or stockholder of the Issuers or any Guarantor, as such, will have any liability for any obligations of the Issuers or the Guarantors under the Notes, the Indenture, this Supplemental Indenture, the Note Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation.  Each Holder of Notes by accepting a Note waives and releases all such liability.  The waiver and release are part of the consideration for issuance of the Notes.  The waiver may not be effective to waive liabilities under the federal securities laws.

1

Exhibit 10.209

4.    NEW YORK LAW TO GOVERN; WAIVER OF JURY TRIAL.  THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.  EACH OF THE ISSUERS AND THE GUARANTORS CONSENTS AND IRREVOCABLY SUBMITS TO THE JURISDICTION OF ANY NEW YORK STATE OR U.S. FEDERAL COURT LOCATED IN THE BOROUGH OF MANHATTAN, CITY OF NEW YORK, COUNTY OF NEW YORK, STATE OF NEW YORK IN RELATION TO ANY LEGAL ACTION OR PROCEEDING (I) ARISING OUT OF, RELATING TO OR IN CONNECTION WITH THIS INDENTURE, AS SUPPLEMENTED, THE NOTES, THE GUARANTEES AND ANY RELATED DOCUMENTS AND/OR (II) ARISING UNDER ANY U.S. FEDERAL OR U.S. STATE SECURITIES LAWS IN RESPECT OF THE NOTES, THE GUARANTEES AND ANY SECURITIES ISSUED PURSUANT TO THE TERMS OF THE INDENTURE, AS SUPPLEMENTED.  EACH OF THE ISSUERS AND THE GUARANTORS WAIVES ANY OBJECTION TO PROCEEDINGS IN ANY SUCH COURTS, WHETHER ON THE GROUND OF VENUE OR ON THE GROUND THAT THE PROCEEDINGS HAVE BEEN BROUGHT IN AN INCONVENIENT FORUM.  EACH OF THE ISSUERS AND THE GUARANTORS, TO THE EXTENT ORGANIZED OUTSIDE OF THE UNITED STATES, SHALL APPOINT CT CORPORATION SYSTEM, 111 EIGHTH AVENUE, 13TH FLOOR, NEW YORK, NY 10011, AS ITS AGENT FOR SERVICE OF PROCESS IN ANY SUCH SUIT, ACTION OR PROCEEDING AND AGREES THAT SERVICE OF PROCESS UPON SAID AUTHORIZED AGENT SHALL BE DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON IT IN ANY SUCH SUIT, ACTION OR PROCEEDING. EACH OF THE ISSUERS AND THE GUARANTORS AGREES TO DELIVER, UPON THE EXECUTION AND DELIVERY OF THIS SUPPLEMENTAL INDENTURE, A WRITTEN ACCEPTANCE BY SUCH AGENT OF ITS APPOINTMENT AS SUCH AGENT. EACH OF THE ISSUERS AND THE GUARANTORS, TO THE EXTENT ORGANIZED OUTSIDE OF THE UNITED STATES, FURTHER AGREES TO TAKE ANY AND ALL ACTION, INCLUDING THE FILING OF ANY AND ALL SUCH DOCUMENTS AND INSTRUMENTS, AS MAY BE REASONABLY NECESSARY TO CONTINUE SUCH DESIGNATION AND APPOINTMENT OF CT CORPORATION SYSTEM IN FULL FORCE AND EFFECT FOR SO LONG AS THE INDENTURE, AS SUPPLEMENTED, REMAINS IN FORCE.  EACH OF THE ISSUERS, THE TRUSTEE AND THE GUARANTORS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS SUPPLEMENTAL INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY.
5.    COUNTERPARTS.  The parties may sign any number of copies of this Supplemental Indenture.  Each signed copy (which may be provided via facsimile or other electronic transmission) shall be an original, but all of them together represent the same agreement.  
6.    EFFECT OF HEADINGS.  The Section headings herein are for convenience only and shall not affect the construction hereof.
7.    THE TRUSTEE.  The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiaries and the Issuers.

2

Exhibit 10.209

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed and attested, all as of the date first above written.
	
		
	BOCA PHARMACAL, LLC, as a 

	Guaranteeing Subsidiary

	    by GENERICS INTERNATIONAL (US), INC., its

	     sole member

	
		
	By:
	/s/ Deanna Voss

	 
	Name: Deanna Voss 

	 
	Title: Assistant Secretary

	
		
	DAVA INTERNATIONAL, LLC, as a

	Guaranteeing Subsidiary

	    by DAVA PHARMACEUTICALS, INC., its

	     sole member

	
		
	By:
	/s/ Deanna Voss

	 
	Name: Deanna Voss 

	 
	Title: Assistant Secretary

	
		
	DAVA CAPITAL MANAGEMENT, INC., as a

	Guaranteeing Subsidiary

	
		
	By:
	/s/ Deanna Voss

	 
	Name: Deanna Voss 

	 
	Title: Assistant Secretary

3

Exhibit 10.209

	
		
	ENDO FINANCE LLC

	  as an Issuer

	    by ENDO LUXEMBOURG FINANCECOMPANY I

	        S.À R.L., its sole member

	
		
	By:
	 /s/ John D. Boyle

	Name:
	 John D. Boyle

	Title:
	A Manager

	
		
	By:
	/s/ Andrew O’Shea

	Name:
	Andrew O’Shea

	Title:
	B Manager

4

Exhibit 10.209

	
		
	ENDO FINCO INC.

	   as an Issuer

	
		
	By:
	/s/ Deanna Voss

	Name: 
	Deanna Voss 

	Title:
	 Secretary

5

Exhibit 10.209

	
		
	ENDO LLC

	  ENDO U.S. INC.

	    each, as a Guarantor

	
		
	By:
	/s/ Deanna Voss

	Name:
	Deanna Voss

	Title:
	Secretary

6

Exhibit 10.209

	
	
	ENDO HEALTH SOLUTIONS INC.

	ENDO PHARMACEUTICALS INC.

	ENDO PHARMACEUTICALS SOLUTIONS INC.

	ENDO PHARMACEUTICALS VALERA INC

	GENERICS INTERNATIONAL (US PARENT), INC.

	GENERICS INTERNATIONAL (US MIDCO), INC.

	GENERICS INTERNATIONAL (US HOLDCO), INC.

	GENERICS INTERNATIONAL (US), INC.

	AMERICAN MEDICAL SYSTEMS HOLDINGS, INC.

	AMERICAN MEDICAL SYSTEMS, INC.

	AMS RESEARCH CORPORATION

	AMS SALES CORPORATION

	LASERSCOPE 

	   each, as a Guarantor

	
		
	By:
	/s/ Deanna Voss

	Name:
	Deanna Voss

	Title:
	Assistant Secretary

7

Exhibit 10.209

	
	
	GENERICS BIDCO I, LLC 

	VINTAGE PHARMACEUTICALS, LLC 

	GENERICS BIDCO II, LLC

	MOORES MILL PROPERTIES LLC

	WOOD PARK PROPERTIES LLC 

	QUARTZ SPECIALTY PHARMACEUTICALS, LLC

	   each, as a Guarantor

	   by GENERICS INTERNATIONAL (US), INC., 

	   its manager

	
		
	By:
	/s/ Deanna Voss

	Name:
	Deanna Voss

	Title:
	Assistant Secretary

8

Exhibit 10.209

	
	
	LEDGEMONT ROYALTY SUB LLC

	   as a Guarantor

	   by ENDO PHARMACEUTICALS SOLUTIONS INC.,

	   its manager

	
		
	By:
	/s/ Deanna Voss

	Name:
	Deanna Voss

	Title:
	Assistant Secretary

9

Exhibit 10.209

	
	
	ENDO LIMITED

	   as a Guarantor

	
		
	By:
	 /s/ Orla Dunlea

	 
	Orla Dunlea

	 
	Title: Director

	
	
	ENDO VENTURES LIMITED

	   as a Guarantor

	
		
	By:
	 /s/ Orla Dunlea

	 
	Orla Dunlea

	 
	Title: Director

	
	
	ENDO MANAGEMENT LIMITED

	   as a Guarantor

	
		
	By:
	 /s/ Orla Dunlea

	 
	Orla Dunlea

	 
	Title: Director

	
	
	ENDO FINANCE LIMITED

	   as a Guarantor

	
		
	By:
	 /s/ Orla Dunlea

	 
	Orla Dunlea

	 
	Title: Director

10

Exhibit 10.209

	
	
	ENDO LUXEMBOURG HOLDING COMPANY S.À R.L. 

	   as a Guarantor

	
		
	By:
	 /s/ John D. Boyle

	Name:
	 John D. Boyle

	Title:
	A Manager

	
		
	By:
	 /s/ Andrew O' Shea

	Name:
	Andrew O' Shea

	Title:
	B Manager

	
	
	ENDO LUXEMBOURG FINANCE COMPANY S.À R.L. 

	   as a Guarantor

	
		
	By:
	 /s/ John D. Boyle

	Name:
	 John D. Boyle

	Title:
	A Manager

	
		
	By:
	 /s/ Andrew O' Shea

	Name:
	Andrew O' Shea

	Title:
	B Manager

	
	
	ENDO LUXEMBOURG FINANCE COMPANY S.À R.L. 

	   as a Guarantor

	
		
	By:
	 /s/ John D. Boyle

	Name:
	 John D. Boyle

	Title:
	A Manager

	
		
	By:
	 /s/ Andrew O' Shea

	Name:
	Andrew O' Shea

	Title:
	B Manager

11

Exhibit 10.209

	
	
	PALADIN LABS CANADIAN HOLDING INC.

	   as a Guarantor

	
		
	By:
	/s/ Mark Beaudet

	Name:
	Mark Beaudet

	Title:
	President

	
	
	PALADIN LABS INC.

	   as a Guarantor

	
		
	By:
	/s/ Mark Beaudet

	Name:
	Mark Beaudet

	Title:
	President

12

Exhibit 10.209

	
	
	ENDO VENTURES BERMUDA LIMITED, as a

	Guarantor

	
		
	By:
	/s/ Laurence S. Smith    

	 
	Name: Laurence S. Smith

	 
	Title:   Director

13

Exhibit 10.209

	
	
	ENDO NETHERLANDS B.V., as a Guarantor

	
		
	By:
	/s/ Blaine T. Davis

	 
	Name: Blaine T. Davis

	 
	Title:   Managing Director A

	
		
	By:
	/s/ Gert Jan Rietberg

	 
	Name: Gert Jan Rietberg

	 
	Title:   Managing Director B

14

Exhibit 10.209

	
	
	WELLS FARGO BANK, NATIONAL ASSOCIATION,

	as Trustee

	
		
	By:
	  /s/ Yana Kislenko

	 
	Name: Yana Kislenko

	 
	Title:   Vice President

15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]